Trial Profile

A Phase 3 Study of Velcade (Bortezomib) Dexamethasone (VD) Versus Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 13 Apr 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Apr 2016 Pooled pharmacogenomics genome-wide association study analysis (n=598) of 3 trials [IFM 2005-01, IFM2007-02, and HOVON-65/GMMG-HD4 ] were published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
17 Mar 2012 Planned patient number is 200 according to European Clinical Trials Database record.
13 Jun 2010 Interim results presented at the 15th Congress of the European Haematology Association.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com